News
PFE
27.05
+1.48%
0.40
Here are the quant ratings of OZEM’s top holdings amid Novo's selloff
Seeking Alpha · 6h ago
CDC Deputy Director Ralph Abraham steps down
Seeking Alpha · 7h ago
Weekly Report: what happened at PFE last week (0216-0220)?
Weekly Report · 15h ago
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Barchart · 15h ago
Option Volatility And Earnings Report For February 23 - 27
Barchart · 18h ago
Assessing Pfizer (PFE) Valuation As Investors Revisit Mixed Returns And Oncology Growth Prospects
Simply Wall St · 1d ago
My 5 Favorite Dividend Stocks to Buy Right Now
The Motley Fool · 1d ago
Notable healthcare headlines for the week: J&J, Masimo and Bayer in focus
Seeking Alpha · 1d ago
Merck: Why Investors Should Remain Bullish Despite Patent Risks
Seeking Alpha · 1d ago
Massive News: Pfizer's 6% Dividend Could Be Safer Than You Think
The Motley Fool · 2d ago
Pfizer: A Risky 6.3% Yield For Income-Oriented Investors
Seeking Alpha · 2d ago
Is Pfizer Stock an Underrated Healthcare Investment Play?
The Motley Fool · 3d ago
Pharmaceutical tariffs still in play despite Supreme Court ruling
Seeking Alpha · 3d ago
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Friday
Benzinga · 3d ago
Moderna Faces Lawsuit From BioNTech Over Next-Generation COVID-19 Shot
Benzinga · 3d ago
Pfizer Initiated at Underweight by Barclays
Dow Jones · 3d ago
Barclays Initiates Coverage On Pfizer with Underweight Rating, Announces Price Target of $25
Benzinga · 3d ago
Pfizer (PFE) Gets a Hold from Goldman Sachs
TipRanks · 3d ago
Moderna sued for violating patent linked to Pfizer/ BioNTech COVID-19 shot
Seeking Alpha · 3d ago
Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash?
NASDAQ · 3d ago
More
Webull provides a variety of real-time PFE stock news. You can receive the latest news about Pfizer through multiple platforms. This information may help you make smarter investment decisions.
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.